Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 16/20 | 0.49 |
| ▸ | ATR | Q13535 | 3/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154101 | 0.82 | PIK3CA (0.53) | MTORPIK3CA | |
| SCHEMBL20138747 | 0.79 | PDCD1 (0.46) | MTORATRPDCD1CD274CHEK1 | |
| SCHEMBL20138793 | 0.79 | PDCD1 (0.46) | MTORATRPDCD1CD274CHEK1 | |
| SCHEMBL23426261 | 0.77 | MTOR (0.43) | MTORATR | |
| SCHEMBL20154102 | 0.73 | MTOR (0.42) | MTORATRPIK3CA | |
| SCHEMBL4018233 | 0.70 | PIK3CA (0.65) | MTORPIK3CA | |
| SCHEMBL8001314 | 0.68 | ATR (0.63) | MTORATRPDCD1CD274CHEK1 | |
| SCHEMBL16121283 | 0.68 | ATR (0.45) | MTORATRPDCD1CD274CHEK1 | |
| SCHEMBL17503359 | 0.68 | ATR (0.45) | MTORATRPDCD1CD274CHEK1 | |
| SCHEMBL12005646 | 0.68 | MTOR (0.41) | MTORATRPDCD1CD274CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| CN-110088100-B | Pyrimidone derivatives as CDC7 inhibitors | 癌症研究科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-03-17 | — | — | US | disclosed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| EP-3538523-B1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3538523-B1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | MTOR 250/4885ATR 450/4885PDCD1 541/4885 |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | MTOR 250/4885ATR 450/4885PDCD1 541/4885 |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | MTOR 250/4885ATR 450/4885PDCD1 541/4885 |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CDC7, CDK7, CDK17 | MTOR 250/4885ATR 450/4885PDCD1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.